Since its original discovery in screens for rapamycin suppressors (Heitman et al., 1991; Sabatini et al., 1994), TOR has been extensively studied in the context of TORC1, and has been shown to stimulate key anabolic cellular processes and inhibit the degradative pathway of autophagy (reviewed in Dibble and Manning, 2013; Loewith and Hall, 2011; Soulard et al., 2009) with crucial roles in metabolic diseases, cancer and aging (Cornu et al., 2014; Sabatini, 2006; Zoncu et al., 2011). This evidence concerns the gene CRTC1 and cancer.